Results 131 to 140 of about 5,070,713 (217)

Therapeutic potential of haptoglobin in a murine model of sickle cell anemia. [PDF]

PLoS One
Dos Santos BC, Dos Santos MNN, Pedroso GA, de Oliveira BB, de Albuquerque DM, de Oliveira NR, Noronha DC, Costa FF, Corat MAF.   +8 more
europepmc   +1 more source

Association of Three HIF‐1α Genotypes With Susceptibility and Severity of Chronic Kidney Disease

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Hypoxic signaling is a critical factor in the pathogenesis of Chronic Kidney Disease (CKD). Hypoxia‐Inducible Factor 1 (HIF‐1) is a transcription factor that is highly expressed in the kidney and is associated with renal tubular hypoxic adaptation. Variation in the HIF‐1α subunit gene has been associated with renal pathologies.
Hanifa Aktar, Shahrzad Ashena, Mohammad Sanaei Ardekani, Shahrzad Movafagh   +3 more
wiley   +1 more source

The Bloodline newsletter : Sickle Cell Data Collection (SCDC) Program quarterly newsletter ; July 2022

Mission: To improve quality of life, life expectancy, and health among people living with sickle cell disease (SCD)

core  

A New Fetal Hemoglobin-Related Phenotype in Sickle Cell Anemia. [PDF]

Am J Hematol
Steinberg MH, Rees DC.
europepmc   +1 more source

Subtotal Versus Total Splenectomy in Children With Sickle Cell Disease: Clinical Outcomes and Splenic Function Assessed by Pocked Red Blood Cell Count

American Journal of Hematology, Volume 101, Issue 10, Page 2654-2658, October 2026.
Alma Al Sibaaie, Abdoulaye Sissoko, Carmen Capito, Christophe Chardot, Mariane de Montalembert, Valentine Brousse, Joséphine Brice, Martina Bevacqua, Camille Roussel, Lucie Dumas, Astan Cissé, Pierre Buffet, Slimane Allali   +12 more
wiley   +1 more source

Real‐World Claims Data on Prescribed Drugs and the Associated Drug–Drug Interaction Risk in Sickle Cell Disease in the United States

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
Real‐world prescription data from 6230 adolescents and adults living with sickle cell disease (SCD) were combined with a drug–drug interaction (DDI) database to characterize the population‐level DDI risk. The findings support a DDI risk assessment for development of novel SCD therapies and during clinical management of SCD.ABSTRACTSickle cell disease ...
Rune Aabjerg Nørgaard, Laura Grenier, Peter Bruun‐Rasmussen, Ifeyinwa Osunkwo, Carolina Säll   +4 more
wiley   +1 more source

The Bloodline newsletter : Sickle Cell Data Collection (SCDC) Program quarterly newsletter ; November 2022

Mission: To improve quality of life, life expectancy, and health among people living with sickle cell disease (SCD)

core  

Cerebral Blood Transit in Sickle Cell Anemia. [PDF]

J Magn Reson Imaging
Richerson WT, Aumann MA, Song AK, Davis S, Milner L, Garza M, Martin D, Davis LT, Pruthi S, Jordan LC, Donahue MJ.   +10 more
europepmc   +1 more source

A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST)

American Journal of Hematology, Volume 101, Issue 10, Page 2666-2671, October 2026.
Kenneth I. Ataga, Pablo Bartolucci, Santosh L. Saraf, Vimal K. Derebail, Adlette Inati, Jeffrey D. Lebensburger, Laurie DeBonnett, Rodolfo D. Cancado, Claire C. Sharpe   +8 more
wiley   +1 more source

Is There a Difference in Occurrence of Complications Between Adults With Hemoglobin SS and Hemoglobin SC Disease: An Extended Systematic Review

European Journal of Haematology, Volume 117, Issue 4, Page 824-837, October 2026.
ABSTRACT Sickle cell disease (SCD) is characterized by both acute and chronic complications. The clinical manifestation of these complications differs between genotypes. Given the large amount of research already published, this systematic review aims to offer a complete overview of types of sickle cell complications between adults in the most common ...
Martijn van der Meer, Kim Velsink, Wing H. Tong, Jan W. Schoones   +3 more
wiley   +1 more source